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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The aim of this review is to evaluate the effectiveness of interventions designed to reduce the rate of falls in people with multiple
sclerosis (MS). Specific objectives include comparing the effectiveness of single, multiple and multifactorial interventions designed to
reduce the rate of falls in people with MS.
B A C K G R O U N D
Multiple sclerosis (MS) is one of the most prevalent diseases of the
central nervous system (CNS) with recent prevalence estimates
indicating that MS directly affects 2.3 million people worldwide
(Browne 2014). Global annual incidence estimates range from
0.07 to 13.75 per 100,000 people (Browne 2014).Wide variations
occur in relation to the prevalence and incidence ofMS, according
to geographic location, with parts ofNorthernEurope andCanada
being the most commonly affected (Browne 2014). It is the most
common disabling neurological disorder among young people.
TraditionallyMS has been categorised according to clinical pheno-
type as primary-progressive, relapsing-remitting, secondary-pro-
gressive and progressive-relapsing (Lublin 1996). However, it has
been suggested that a classification based on clinical and radio-
logical activity be instigated (Lublin 2014). MS is an immune-
mediated disease characterised by inflammatory demyelination
and neurodegeneration within the CNS. This damage to the
CNS structures in turn leads to impairments in cognition, mus-
cle strength, muscle tone, sensation, coordination and gait, all of
which are associated with an increased risk for falls. Despite the
recent increased availability of disease-modifying medical treat-
ments and their potential to delay the clinical progression of MS,
falls continue to present as a common and serious health concern
in people with this disease.
Description of the condition
1Interventions for preventing falls in people with multiple sclerosis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fall rates of 56% have been reported among people withMS (mea-
sured using prospective measures) in a recent meta-analysis of 537
individuals, with 37% of the study population falling recurrently
(Nilsagard 2015). This study demonstrated that most falls oc-
curred indoors (65%) between 6 a.m. and 6 p.m. (75%). In ad-
dition, primary progressive MS and Expanded Disability Severity
Scale (EDSS) (Kurtzke 1983) levels of 4.0 and 6.0 were associ-
ated with significantly increased odds of falls (P < 0.05). The falls
rate was also lower in women than men (relative risk (RR) 0.80;
95% confidence interval (CI) 0.67 to 0.94) and decreased with
increasing age (RR 0.97 for each year, CI 0.95 to 0.98). In a study
by Matsuda 2011, 28% of people with MS who had reported to
have fallen (265 of a total of 455 respondents) suffered a fracture.
A population-based European study reported that the incidence
rate of fracture was significantly higher among people with MS
than age- and gender-matched peers without MS (Bazelier 2011).
People with MS with a history of falls report significantly poorer
physical and psychological health status comparedwith non-fallers
with MS (Coote 2013). Falls can further have an adverse impact
on fear of falling and falls self-efficacy, and can contribute to ac-
tivity curtailment, physiological deconditioning, loss of indepen-
dence, and institutionalisation (Finlayson 2010; Matsuda 2012).
A recent systematic review with meta-analysis identified four fac-
tors significantly associated with falls in people with MS: balance
dysfunction, the use of a mobility aid, cognitive dysfunction, and
progressive MS subtype (Gunn 2013). Given the high prevalence
of falls among people with MS and the associated serious and
wide-ranging consequences, an increased number of randomised
controlled trials have evaluated the effect of falls prevention inter-
ventions among people with MS.
Description of the intervention
Toour knowledge there currently is no classificationof falls preven-
tion interventions in theMS literature. The effectiveness of several
categories of falls prevention interventions has been reviewed sys-
tematically among older adults (Gillespie 2003; Gillespie 2012)
and people post-stroke (Verheyden 2013) by Cochrane. These cat-
egories are also used by the few researchers that have examined
fall prevention or management in MS. However the Prevention
of Falls Network Europe (ProFaNE) (Lamb 2005; Lamb 2011)
proposes the following categories for older adults: exercises, medi-
cation, surgery, management of urinary incontinence, fluid or nu-
trition therapy, psychological intervention, environment/assistive
technology, environment (social environment), knowledge inter-
ventions and other interventions. In the ProFaNE taxonomy, in-
terventions are also classified as single interventions, multiple in-
terventions or multifactorial interventions. A single intervention
consists of only one intervention component which is delivered to
all participants in the intervention group, (e.g. exercise). Multiple
interventions consist of a combination of two or more interven-
tion components, delivered to all of the participants in the in-
tervention group, (e.g. exercise plus psychological interventions).
Multifactorial interventions consist of more than one intervention
component, but participants receive different combinations of in-
terventions based on an individual assessment to identify potential
risk factors for falls.
For the purpose of this review, wewill include all potential falls pre-
vention interventions and these interventions will be categorised
according to the ProFaNE taxonomy (Lamb 2005; Lamb 2011).
How the intervention might work
Falls prevention interventions are designed to minimise known
modifiable personal, task and environmental risk factors for falling,
and thereby prevent falls and associated injuries. Interventions
are designed to reduce the falls rate by targeting improvement in
personal risk factors, e.g. reduced balance function, and incorpo-
rate exercises to improve joint flexibility, muscle strength, reaction
times and coordination. Other interventions are aimed at improv-
ing non-physical personal risk factors, e.g. the presence of cogni-
tive impairment, and include strategies to promote risk awareness,
planning and attention. Interventions are also designed to reduce
falls by promoting improved task performance, e.g. safe mobility
aid use, and include participant education regarding task analysis
and planning. Interventions are additionally designed to amelio-
rate the falls rate by addressing environmental risk factors, e.g.
home environmental modifications, and include the provision of
aids for personal care.
Single component interventions are designed to address and ame-
liorate specific risk factors for falling. For example, in Cochrane
Reviews focusing on falls prevention interventions among older
adults, vitamin D prescription interventions have been shown to
be effective in reducing falls rates among older adults in care facil-
ities (Cameron 2012) and exercise interventions have been shown
to be effective in reducing falls rates among older adults living in
the community (Gillespie 2012). There is potential for this im-
provement to be mediated indirectly through the effect of exercise
on balance function and mobility functions. To date in the MS
literature, of the few falls interventions that have been evaluated,
most have predominantly used combinations of education and ex-
ercise, targeting mobility, balance, and falls self-efficacy outcomes.
The association between balance, mobility impairments, and falls
inMS is complex. Programmes focused on balance and stability in
older adult populations have been shown to decrease falls in other
populations (Gillespie 2012) whereas those that target mobility
alone have tended to be either ineffective or to increase falls in
older adult populations (Gillespie 2012).
Multiple component interventions aim to reduce several compo-
nents of falls risk rather than dealing with single risk factors. Com-
monly, multiple component interventions focus on two or more
common risk factors and provide these to all participants, regard-
less of their exact risk status. However, there is no assessment and
individual tailoring of the intervention to risk factors. There is
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some evidence that multiple component interventions may reduce
the rate of falls and the risk of falling in older people living in the
community (Gillespie 2012).
The rationale underlying multifactorial interventions is that par-
ticipants undergo an assessment for risk of falling, and a tailored
intervention is provided based on their modifiable risk factors.
Gillespie 2012 found some evidence that multifactorial interven-
tions may reduce the rate of falls (i.e. the total number of falls per
unit of person time that falls were monitored), but not the risk of
falling (i.e. the number of people who fell once or more among
older people living in the community).
Why it is important to do this review
The incidence of falls in people with MS is three times higher
than that in older people, yet recently published clinical guide-
lines (NGC 2014) do not outline an evidence-based approach to
falls interventions among people withMS. This topic has been ex-
amined and reviewed systematically among older adults (Gillespie
2003; Cameron 2012; Gillespie 2012) and people post-stroke
(Verheyden 2013) by Cochrane. Therefore there is a clear clini-
cal need for synthesised information regarding the effectiveness of
falls prevention interventions among people with MS. This clin-
ical need is relevant across multiple disciplines and multiple set-
tings (home, community, clinical setting). A Cochrane systematic
review of this topic has the potential to guide clinical decisions
regarding care pathways for people with MS who are at risk of
falling, and ultimately to improve quality of life of people with
MS.
O B J E C T I V E S
The aim of this review is to evaluate the effectiveness of interven-
tions designed to reduce the rate of falls in people with multiple
sclerosis (MS). Specific objectives include comparing the effective-
ness of single, multiple and multifactorial interventions designed
to reduce the rate of falls in people with MS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) and quasi-
randomised trials, including randomised and quasi-randomised
cluster and cross-over trials. We will include all trials regardless of
methodological quality.
Types of participants
We will include adults 18 years of age or older, male and female,
with clinically definite MS. People with the clinical diagnosis of
MS according to the ICD-8 (code 340) (ICD-8 1965), and the
McDonald criteria and subsequent revisions (Schumacher 1965;
Poser 1983; McDonald 2001; Polman 2005; Polman 2011) will
be included. All subgroups of MS such as relapsing remitting, pri-
mary progressive and secondary progressive MS, and people at any
time since diagnosis will be included. People with neurological
and non-neurological comorbidities that may affect falls, e.g. de-
mentia, Parkinson’s disease, and recent orthopaedic surgery, will
be excluded.
Types of interventions
Falls prevention interventions will be considered to be any pro-
gramme in which the primary or secondary aim is to reduce the
rate of falls. Some anticipated falls prevention interventions may
include: exercise (e.g. aerobic, strengthening, balance), medical in-
tervention (e.g. supplementation with vitamin D), psychological
(e.g. cognitive behavioural therapy interventions), environment
modifications (e.g. the provision of hip protectors, adaptations to
homes), assistive technology interventions (e.g. provision of aids
for personal care and protection and personal mobility, eyeglasses,
hearing aids, personal alarm systems), surgical interventions (e.g.
surgery to address a comorbidity such as hip or knee replacement
for osteoarthritis) or other interventions (e.g. educational inter-
ventions designed to increase knowledge relating to falls preven-
tion). Acceptable control interventions will include: no treatment,
wait-list control, usual care control and interventions that are not
intended to reduce falls rate or the number of fallers, (e.g. educa-
tional interventions to promote physical activity engagement).
Types of outcome measures
Outcomemeasures will be examined prior to and at the end of the
intervention and at the end of follow-up (e.g. 3-, 6- or 12-month
follow-up periods).
Primary outcomes
• The rate of falls (the number of falls per person year),
measured using both retrospective and prospective measures,
recommended by the International MS Falls Prevention Research
Network (IMSFPRN) as the primary outcome for falls
prevention trials.
• The number of falls per person.
• The number of recurrent or frequent fallers.
• The number of adverse events resulting from the
intervention, e.g. incidence of fall-related injuries.
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Secondary outcomes
• Falls risk, measured using measures including, but not
restricted to, the Physiological Profile Assessment.
• Quality of life (including psychological aspects such as fear
of falling), measured using measures including, but not restricted
to, the Multiple Sclerosis Impact Scale-29 (Hobart 2001).
• Balance function, measured using measures including, but
not restricted to, the Berg Balance Scale (Berg 1989), Mini-
BEST test (Franchignoni 2010).
• Psychological aspects such as fear of falling; activity
curtailment due to fear of falling.
• Cognition, measured using measures including, but not
restricted to, the Symbols Digit Modalities Test (SDMT) (Smith
1982).
• Measures of MS disease progression, including but not
restricted to the Expanded Disease Severity Scale (EDSS)
(Kurtzke 1983), and Patient Determined Disease Steps (PDDS)
(Hohol 1995).
• Measures of mobility including, but not restricted to the Six
Minute Walk Test (Fry 2006), and MS Walking Scale-12
(Hobart 2003).
• Measures of functional outcome, including but not
restricted to the Functional Independence Measure (Keith 1987).
• Self-reported fatigue, measured using measures including,
but not restricted to, the Modified Fatigue Impact Scale (MFIS)
(Fischer 1999).
• Measures of participation, including but not restricted to
the Community Integration Measure (McColl 2001).
• Outcomes that reflect cost, service utilisation and care
burden.
Self-report and objective measures will be included.
Search methods for identification of studies
A systematic search without language or date restrictions will be
conducted using the optimally-sensitive strategy developed for
Cochrane to identify all relevant published and unpublished RCTs
(Lefebvre 2011). We will employ the services of a professional
translator if required, for study selection and data extraction.
Electronic searches
The Information Specialist will search the Trials Register of the
CochraneMultiple Sclerosis and Rare Diseases of theCNSGroup,
which, among other sources, contains trials from:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (2016, most recent issue);
• MEDLINE (PubMed) (1966 to date);
• Embase (EMBASE.com) (1974 to date);
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCOhost) (1981 to date);
• Latin American and Caribbean Health Science Information
Database (LILACS) (Bireme) (1982 to date);
• ClinicalTrials.gov (www.clinicaltrials.gov); and
• World Health Organization (WHO) International Clinical
Trials Registry Platform (apps.who.int/trialsearch).
Information on the Trials Register or the ReviewGroup and details
of the search strategies used to identify trials can be found in
the ’Specialised Register’ section within the Cochrane Multiple
Sclerosis and Rare Diseases of the CNS Group module.
The keywords that will be used to search for trials for this review
are listed in Appendix 1.
We will extend the search to other resources, including:
• PsycINFO (1806 to date); and
• Physiotherapy Evidence Database (PEDro) (1999 to date).
Searching other resources
We will:
• handsearch the reference lists of all retrieved articles, texts
and other reviews on the topic;
• contact researchers active in this field for additional data, if
necessary; and
• contact principal authors of unpublished manuscripts to
ask if they are willing to disclose their unpublished data.
Data collection and analysis
Selection of studies
Titles and abstracts of the citations retrieved by the literature search
will be screened independently by two review authors (SH, SC)
for inclusion or exclusion, based on predetermined inclusion cri-
teria. The full text of potentially relevant studies will be selected
for further assessment and at least two authors will ascertain and
agree on eligibility based on the full article. The eligibility (on
the basis of the information available in the published data) of
these studies will be evaluated independently. Papers assessed in
full text that do not meet the inclusion criteria will be listed in
the ’Characteristics of excluded studies’ table with the reasons for
exclusion. Any disagreement regarding inclusion will be resolved
by discussion, or by referral to a third assessor (RG) if necessary.
Data extraction and management
For each included study, two review authors (SH, RG) will in-
dependently extract data from the selected trials using standard-
ised forms and enter the data into the RevMan software (Review
Manager 2014). We will extract data on the following:
• study design;
• characteristics of participants (number, setting, age, type of
MS, EDSS score);
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• inclusion and exclusion criteria;
• brief description of experimental intervention;
• brief description of control intervention;
• methodological quality of studies;
• description of setting;
• description of outcomes;
• date of study and location of study.
Disagreements will be discussed and resolved by consensus among
the review authors.
Assessment of risk of bias in included studies
The risk of bias for all included studies will be independently as-
sessed by two review authors (SH, SC) using the ’Risk of bias’
tool outlined in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). The domains are: sequence genera-
tion, allocation concealment, blinding, incomplete outcome data,
selective outcome and other biases. Disagreements among the re-
view authors on the methodological quality of the identified stud-
ies will be discussed and resolved by group consensus.
We will use the summary quality assessment at the analysis stage
as a means of interpreting the results. For each dimension and for
the summary assessment we will assign the ’Risk of bias’ categories
(Higgins 2011) as:
• low risk of bias, plausible bias unlikely to seriously alter the
results;
• unclear risk of bias, plausible bias that raises some doubt
about the results; and
• high risk of bias, plausible bias that seriously weakens
confidence in the results.
Assessing the quality of the body of evidence using the
GRADE approach
We will assess the quality of the evidence using the GRADE ap-
proach as outlined in the GRADE handbook in order to assess the
quality of the body of evidence relating to the following outcomes
for the main comparisons:
• the rate of falls;
• the number of fallers and frequent fallers;
• the number of adverse events;
• falls risk; and
• quality of life.
We will use the GRADEpro Guideline Development Tool to im-
port data from Review Manager 5.3 (Review Manager 2014) in
order to create a ’Summary of findings’ table. As per the Cochrane
Handbook for Systematic Reviews of Interventions guidelines, the
’Summary of Findings’ table will include the following informa-
tion (Higgins 2011): a list of all important outcomes; a measure of
the typical burden of these outcomes; absolute and relative mag-
nitude of effect; numbers of participants and studies addressing
these outcomes; a rating of the overall quality of evidence for each
outcome and a space for comments.
A summary of the intervention effect and a measure of quality for
each of the above outcomes will be produced using the GRADE
approach. The GRADE approach uses five considerations (study
limitations, consistency of effect, imprecision, indirectness and
publication bias) to assess the quality of the body of evidence
for each outcome. The evidence can be downgraded from ’high
quality’ by one level for serious (or by two levels for very serious)
limitations, depending on assessments for risk of bias, indirectness
of evidence, serious inconsistency, imprecision of effect estimates
or potential publication bias.
Measures of treatment effect
According to the study characteristics, we will determine the treat-
ment effect of:
• falls intervention versus another intervention (not designed
to reduce falls);
• falls interventions versus no treatment;
• falls intervention versus another falls intervention, e.g.
single exercise intervention versus multiple component exercise
plus education intervention.
According to the type of outcomes reported we will use the fol-
lowing effect measures:
• dichotomous data: odds ratio (OR), risk ratio (RR) or risk
difference (RD); and
• continuous data: mean difference (MD) or standardised
mean difference (SMD) if the studies assess the same outcome
but measure it in a variety of ways (for example, SF-36,
MSQOL-54).
A rate ratio (RaR) and 95%confidence interval (CI) will be used to
compare the rate of falls between intervention and control groups.
For risk of falling and number of adverse events we will use a risk
ratio (RR) and 95% CI based on the number of people falling and
the number of people reporting adverse events in each group.
Unit of analysis issues
Data analysis will take into account the level at which randomisa-
tion occurred (e.g. cluster-randomised trials; cross-over trials, and
repeated measurements).
Dealing with missing data
If trial data are insufficient or missing, we will attempt to obtain
additional information from the authors of included studies by
personal communication. Our method of dealing with missing
data will depend on the nature of the missing data. If the data are
missing at randomwe will analyse only the available data (ignoring
the missing data). If the data are not missing at random we will
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consider the followingoptions, in consultationwith the statistician
on our review team (CW):
1. imputing the missing data with replacement values, and
treating these as if they were observed (e.g. last observation
carried forward, imputing an assumed outcome such as assuming
all were poor outcomes, imputing the mean, imputing based on
predicted values from a regression analysis);
2. imputing the missing data and accounting for the fact that
these were imputed with uncertainty (e.g. multiple imputation,
simple imputation methods (as point 1) with adjustment to the
standard error); or
3. using statistical models to allow for missing data, making
assumptions about their relationships with the available data.
Assessment of heterogeneity
We will calculate the I2 statistic for each pooled estimate to as-
sess the impact on statistical heterogeneity. The I2 statistic may be
interpreted as the proportion of total variation among effect esti-
mates that is due to heterogeneity rather than sampling error, and
it is intrinsically independent of the number of studies. When the
I2 is < 30% there is little concern about statistical heterogeneity
(Higgins 2011). If there is statistical heterogeneity we will use ran-
dom-effects models to take account of the between-study variation
in our findings (Higgins 2011). Where there is substantial clinical
heterogeneity (e.g. in the nature of interventions) then these will
be analysed in homogenous subgroups as described at Subgroup
analysis and investigation of heterogeneity.
Assessment of reporting biases
To estimate the influence of unpublished papers on the overall ef-
fects, and if a sufficient number of studies are identified (at least 10
studies), contour-enhanced funnel plots of effect estimates against
their standard errors (on a reversed scale) will be used.
Data synthesis
We will perform separate analyses for trials comparing an active
falls prevention intervention with ‘treatment as usual’, or with a
‘placebo’ control intervention, and trials comparing two active falls
prevention interventions.
We will analyse the data using Review Manager 2014. We will
decide whether or not to performmeta-analyses based on the sim-
ilarity of the included trials. If we cannot carry out meta-analysis
because of substantial differences between studies or when there
is only one study identified, we will present results in a forest plot
(with the pooled summary of outcomes suppressed) and provide
a narrative/qualitative review. A power analysis will determine if
statistical pooling of data will be appropriate to complete a meta-
analysis. In the case of sufficient power, the data of individual tri-
als will be pooled for each outcome using a fixed-effect model (if
heterogeneity is not present (I2 < 30) and using a random-effects
model if heterogeneity is present (I2≥ 30).
Subgroup analysis and investigation of heterogeneity
If we identify a sufficient number of RCTs we will undertake
subgroup analyses to establish if the following subgroups affect
overall effects:
• participant-related characteristics (e.g. type of impairment
at baseline: participants with muscle weakness, participants with
ataxia, etc.; age; time since diagnosis of MS; type of MS, level of
impairment at baseline; adherence to intervention);
• intervention-related characteristics (e.g. type of falls
prevention intervention, duration of intervention; frequency of
intervention; intensity of intervention);
• study design characteristics (e.g. type of comparison, type
of falls outcome measurement, retrospective falls rate versus
prospective falls rate).
Sensitivity analysis
We will perform sensitivity analysis to address the methodological
quality of the trial by including or excluding trials with moderate
or high risk of bias as described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011).
A C K N OW L E D G E M E N T S
Nil
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A P P E N D I C E S
Appendix 1. Keywords for searching the MS Group Register
((((((“falls”[Title/Abstract]) OR “recurrent falls”[Title/Abstract]) OR “reduced falls”[Title/Abstract]) OR “falls prevention”[Title/Ab-
stract])) AND (((“Tertiary Prevention”[Mesh]) OR “intervention”[Title/Abstract]) OR “prevention”[Title/Abstract]))
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